Phylogica signs licensing deal, collaborates with UWA
18 October, 2005 by Ruth BeranPhylogica (ASX:PYC) has signed a licensing deal with Massachusetts General Hospital and Johns Hopkins University to give the Perth-based company access to a new genetic screening technology.
Positive FDA meeting speeds Mesoblast trials
17 October, 2005 by Helen SchullerMelbourne-based Mesoblast (ASX:MSB) has accelerated its clinical program for obtaining regulatory approvals for its adult stem cell platform technology following a successful pre-investigational new drug (IND) meeting with the US FDA.
Queensland Biobus stops at Gympie
17 October, 2005 by Helen SchullerThe Queensland BioBus is stopping in Gympie this week to encourage more young people to take up a career in science.
Chinese companies invest in Melbourne
14 October, 2005 by Ruth BeranMelbourne biotech is benefiting from a recent business mission to China led by the city's Lord Mayor John So.
In brief: Living Cell Technologies, Phosphagenics, Rockeby, Antisense, Prima, Proteome Systems
14 October, 2005 by Staff WritersLiving Cell Technologies (ASX:LCT) has appointed US based neuroscientist Dr Dwaine F Emerich as chief scientific officer of LCT BioPharma. He has been LCT's US vice-president of research since 2003, joining the company from Sertoli Technologies.
Resonance Health patent granted
13 October, 2005 by Ruth BeranPerth based Resonance Health (ASX:RHT) has been granted its first European patent.
Funding for medical research and Thank You Day campaign launch
13 October, 2005 by Susan WilliamsonThe latest commonwealth government funding announcement for health and medical research will see AUD$292 million allocated to more than 600 projects across 52 Australian universities, hospitals and medical research institutes.
Avantogen signs license agreement with Hawaii Biotech
12 October, 2005 by Helen SchullerAvantogen (ASX:ACU), formerly Australian Cancer Technology, has signed a worldwide, nonexclusive license agreement with Hawaii Biotech to evaluate Avantogen's proprietary adjuvant GPI-0100 with a series of vaccines.
Anadis to sell Travelan in USA
12 October, 2005 by Ruth BeranMelbourne biopharmaceutical company Anadis (ASX:ANX) has received legal advice that its over-the-counter traveller's diarrhoea product, Travelan, complies with all US federal and state regulations for sale in the dietary and medical foods categories.
AtCor Medical to list on ASX in November
12 October, 2005 by Ruth BeranSydney-based devices company AtCor Medical has lodged its prospectus for an initial public offering (IPO) to raise AUD$15 million for expanding the US marketing and sales of its cardiovascular diagnostic device, SphygmoCor.
Starpharma secures full ownership of VivaGel technology
11 October, 2005 by Helen SchullerMelbourne drug developer Starpharma (ASX:SPL) has acquired outright ownership of its VivaGel technology following changes to licence arrangements that were executed when Starpharma was spun-out of the Biomolecular Research Institute (BRI) in 1996.
Solbec's managing director resigns
11 October, 2005 by Ruth BeranPerth-based Solbec Pharmaceuticals' (ASX:SBP ) managing director, Stephen Carter, has resigned.
SciGen signs US$145m hep B distribution deal
10 October, 2005 by Helen SchullerSingapore-based generics company SciGen (ASX:SIE) has signed a Chinese distribution agreement worth at least US$145 million (AUD$191.6 million) with Hefei Life Science Park Investment & Development (HID) for its hepatitis B product, Sci-B-Vac.
Medical Developments International appoints new CEO
10 October, 2005 by Ruth BeranMelbourne-based Medical Developments International (ASX:MVP, MDI) has appointed Dr Simon Fisher as its new CEO, starting today.
In brief: Circadian, Metabolic, Mesoblast
07 October, 2005 by Ruth BeranAfter 21 years as Circadian's (ASX:CIR) founding chairman Sir Peter Derham retired at the conclusion of the company's AGM yesterday. Circadian managing director Leon Serry said that Sir Peter was stepping down because he's now 80 years of age.
